Loading organizations...
Based in New York, New York, BioSapien is a pre-clinical biotechnology company that develops 3D-printed biodegradable implants designed for localized and sustained drug delivery directly to solid tumor sites. The startup utilizes its proprietary MediChip platform to administer FDA-approved therapeutics targeting oncology indications such as pancreatic, colorectal, lung, and breast cancers while minimizing adverse systemic side effects. Operating with a core team of under fifteen employees, the enterprise has secured approximately $3 million in total funding to advance its medical devices through the federal regulatory approval pathway. BioSapien is backed by venture capital firms and institutional investors including SOSV, Hikma Ventures, and the National Science Foundation, while its technology has garnered interest from specialists at Memorial Sloan Kettering and MD Anderson. The targeted drug delivery organization was officially founded in 2018 by Dr. Khatija Ali.
BioSapien has raised $10.0M across 2 funding rounds.
BioSapien has raised $10.0M in total across 2 funding rounds.
BioSapien has raised $10.0M across 2 funding rounds. Most recently, it raised $8.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $8M Seed | — | Global Ventures, SOSV | Announced |
| Nov 1, 2021 | $2M Seed | — | Breakthrough Energy Ventures, Darco Capital, Northpond Ventures, SOSV, TET Ventures, Mark Cuban | Announced |
BioSapien is a late-stage preclinical biotech company founded in 2018, specializing in minimally invasive drug delivery platforms for cancer treatment.[1][2] Its flagship product, MediChip™, is a 3D-printed biocompatible patch that delivers targeted chemotherapy directly to tumors, reducing systemic side effects like nausea and fatigue while enabling sustained local dosing for lower gastrointestinal and solid tumors.[1][2][3][5] Serving oncologists, surgeons, and patients with inoperable or hard-to-treat cancers, MediChip addresses the limitations of systemic chemotherapy by shrinking tumors, easing symptoms, and potentially enabling surgery—backed by $9.06M in total funding, including a recent $5.5M pre-Series A round to launch UAE clinical trials in Q2 2025.[1][3]
The company demonstrates strong growth momentum: global patents issued in 2023 across multiple regions (expiring 2039), acceptance into accelerators like HUB71, and partnerships with Abu Dhabi hospitals, positioning it for rapid clinical advancement in a $247B global cancer drug delivery market.[2][3][4][5]
BioSapien was founded in 2018 in San Diego, California, by Dr. Khatija Ali, a visionary leader driven by a personal question: "Shouldn’t fighting cancer be about regaining control, not losing it?"[2][3][4] Ali, leveraging over 100 years of combined team expertise from academia, medicine, and engineering, developed MediChip™ to revolutionize localized cancer therapy.[2]
The idea emerged from frustration with systemic chemo's harsh side effects and uneven tumor response, leading to pre-seed funding of $250K in 2019 from friends, family, RebelBio, and IndieBio.[2] Pivotal moments include regulatory approvals in 2022, global patent issuances in 2023, and funding escalations—reaching $3M by 2024 and $9.06M overall with recent rounds like $1.8M and $5.5M pre-Series A led by Global Ventures.[1][2][3][5] These milestones fueled progression to late-stage preclinical status and UAE trial preparations.[3]
BioSapien rides the wave of precision oncology and localized drug delivery, fueled by rising cancer incidence, demand for personalized medicine, and 3D printing's maturation in pharma (e.g., competitors like Triastek).[1][4] Timing aligns with post-2020 surges in cancer care spending ($208.9B in US alone) and MENA's biotech push—UAE's oncology focus, genetic diversity, and infrastructure enable BioSapien's trials and scaling.[3][4][5]
Market forces favor it: $247B global cancer drug delivery sector (colorectal subset at $19B+), unmet needs in minimally invasive options amid chemo resistance and surgery limitations.[3] BioSapien influences the ecosystem by pioneering MENA biotech innovation, partnering with top hospitals, and demonstrating scalability beyond cancer—potentially disrupting $246B+ markets while lowering healthcare costs.[2][4]
BioSapien is primed for breakout with Q2 2025 UAE trials, manufacturing expansion, and talent growth, targeting 1M patients by 2035 via MediChip's adaptable platform.[2][3] Trends like AI-driven personalization, 3D bioprinting, and global oncology investments will accelerate its path to Series A and multi-tumor approvals, evolving from San Diego startup to global leader in patient-empowering biotech.[1][4]
This positions BioSapien to transform cancer from a systemic battle into a targeted victory—fulfilling its mission to advance human well-being through innovation that reclaims control for patients.[2]
BioSapien has raised $10.0M in total across 2 funding rounds.
BioSapien's investors include Global Ventures, SOSV, Breakthrough Energy Ventures, Darco Capital, Northpond Ventures, Tet Ventures, Mark Cuban.
